First-in-Class Intracellular Delivery Platform
COMED Hooks is designed to carry therapeutics inside the cell—reaching targets conventional biologics can't touch.
Validated in the lab. Advancing across pancreatic cancer, malaria and SMA.
Turning an Endogenous Biological Pathway into a Delivery Route
COMED Hooks are engineered antibody-based constructs that tether onto the body's own transport systems, carrying antibodies, proteins, peptides, enzymes, and nucleic acids directly into the cytoplasm.
Expanding
the Druggable Landscape
Our most advanced program targets KRAS G12V in pancreatic cancer—a driver with no FDA-approved targeted therapy.
Malaria and spinal muscular atrophy programs are advancing behind it, built on the same platform.
Demonstrated in the Lab, Confirmed in Living Models
Efficient, reproducible intracellular uptake confirmed via live-cell imaging and flow cytometry across multiple pancreatic cancer cell models.
Selective binding to KRAS G12V confirmed, with no measurable binding to the wild-type protein
Significant tumor growth suppression demonstrated in a living preclinical model, with favorable tolerability
Built to Solve an Unmet Medical Need
Founded in 2019 following a personal encounter with late-stage cancer, COMED Therapeutics assembled a team spanning molecular biology, genetics, pharmacokinetics, and medicine—now including a scientific advisory board with academic and industry leadership across Europe and the US, and advancing breakthrough discoveries toward clinical application.
Latest from COMED
COMED's latest scientific advances, company announcements, publications, strategic partnerships, and events shaping the future of intracellular therapeutics.
COMED Named Finalist for Start-Up Business of the Year at the 2026 Malta Business Awards
COMED Therapeutics has been named one of three finalists for Start-Up Business of the Year at the 2026 Malta Business Awards.
COMED Hooks Increase PI-Positive Cells by 69% in CAPAN-2 Cells
An independent study in CAPAN-2 pancreatic cancer cells found 68.7% more PI-positive objects following treatment with COMED Hooks versus matched nLNP controls.
Beyond Tumor Control: Evidence of Cell-State Reprogramming
An independent proteomic analysis of COMED’s pancreatic cancer program provides evidence of cell-state reprogramming following treatment with COMED Hooks.
Whether you're exploring a partnership, evaluating an investment, or curious about the science—we'd like to hear from you.